The present invention is directed to oxazolobenzimidazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
本发明涉及
噁唑苯并咪唑衍
生物,其是代谢型谷
氨酸受体的增强剂,特别是mGluR2受体,可用于治疗或预防与谷
氨酸功能障碍有关的神经和精神障碍以及代谢型谷
氨酸受体参与的疾病。本发明还涉及包含这些化合物的制药组合物,以及使用这些化合物和组合物预防或治疗代谢型谷
氨酸受体参与的这些疾病。